Heterogeneous HER2 gene amplification: Impact on patient outcome and a clinically relevant definition

American Journal of Clinical Pathology

Volumn 136, Issue 2, 2011, Pages 266-274

  Bartlett, Alastair I ^a   Starcyznski, Jane ^b   Robson, Tammy ^a   MacLellan, Alex ^a   Campbell, Fiona M ^a   Van De Velde, Cornelis J H ^c   Hasenburg, Annette ^d   Markopoulos, Christos ^e   Seynaeve, Caroline ^f   Rea, Daniel ^g   Bartlett, John M S ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Amplification; Breast; HER2; Heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CHROMOSOME 17; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTICENTER STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79961007548     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP0EN6AQMWETZZ     Document Type: Article

References (21)

1. Walker RA, Bartlett JMS, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
3. Ellis IO, Bartlett J, Dowsett M, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237. (Pubitemid 38338829)
4. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol. 2000;53:890-892.
5. Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008;14:7861-7870.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
7. Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373:1681-1692.
8. Bartlett JMS, Ibrahim M, Jasani B, et al. External quality assurance of HER2 FISH and ISH testing: three years of the UK National External Quality Assurance Scheme. Am J Clin Pathol. 2009;131:106-111.
9. Miller KD, Ibrahim M, Barnett S, et al. Technical aspects of predictive and prognostic markers in breast cancer: what UKNEQAS data shows. Curr Diagn Pathol. 2007;13:135-149. (Pubitemid 46518122)
10. Bempt IV, Drijkoningen M, Wolf-Peeters C. The complexity of genotype alterations underlying HER2-positive by breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol. 2007;19:552-557. (Pubitemid 47508860)
11. Farabegoli F, Santini D, Ceccarelli C, et al. Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry. 2001;46:50-56. (Pubitemid 32216738)
12. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611-612.
13. Bartlett JMS, Brookes CL, Robson R, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. J Clin Oncol. 2011 29;1531-1538.
14. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ill trial in hormone sensitive postmenopausal early breast cancer [abstract]. Cancer Res. 2009;69(suppl 2):67S. Abstract 15.
15. van de Velde CJH, Rea DW, Seynaeve C, et al. Adjuvant tamoxifen and exemestance in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321-331.
16. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182. (Pubitemid 36245750)
17. Bilous M. HER2 testing recommendations in Australia. Pathology. 2001;33:425-427. (Pubitemid 34032945)
18. Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11:266-274.
19. Sauter G, Lee J, Bartlett JMS, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
20. Bartlett JMS, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol. 2008;130:920-926.
21. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-114. (Pubitemid 36197611)